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Abstract 
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general population is 
affected, and in Italy the prevalence is estimated to be 19.8%. The Allergic Rhinitis and its Impact on Asthma (ARIA) 
international document underlined that the prevalence of severe or refractory or overlapping rhinitis is increasing and 
represents a non-negligible socio-economic burden. In general, despite the social healthcare costs, allergic rhinitis 
remains underestimated, not sufficiently controlled and often undertreated.
Aim of the study: In this multi-center Italian observational and prospective study we assessed the control of AR in 
patients (> 16 years) without previous asthma diagnosis, referred to Allergy Centers.
Methods: Patients of both sexes and older than 16 with rhinitis symptoms and without asthma were studied. A Vis-
ual Analogue Scale (VAS) and the CARAT (Control of Allergic Rhinitis and Asthma Test) were used as patient reported 
outcome. The possible causes of poor control of AR, as per protocol, were assessed accordingly.
Results: We observed 250 patients in a real-life setting: more than 60% of them had an uncontrolled AR, only about 
50% used multiple medications, and only a minority were receiving allergen immunotherapy.
Conclusion: This survey, conducted in a real-life setting, confirmed that AR is overall poorly controlled. The VAS 
assessment well correlates with the structured CARAT questionnaire and with the relevant symptoms of AR.
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Background
Allergic Rhinitis (AR) is a high-prevalence disease. In 
Europe about 25% of the general population is affected 
and in Italy, the prevalence is estimated to be 19.8% [1]. 
The Allergic Rhinitis and its Impact on Asthma (ARIA) 
international document [2] underlined that severe or 
refractory or mixed forms of AR are increasing and 
represent a not negligible socio-economic burden [3]. 
In addition, it was observed that more than one half of 
patients use multiple medications, but many of them 
don’t feel satisfied with the symptoms scores [4]. Finally, 
since AR is considered a trivial disease, many patients do 
not seek medical care or specific diagnosis and primar-
ily refer to pharmacies for self medications [5], or refer 
to alternative/complementary medicines [6], whereas 
allergen specific immunotherapy (AIT) is neglected [7]. 
Currently, topical/systemic antihistamines and intranasal 
corticosteroids are considered the first-line therapy, but 
many other treatments (such as decongestants, cromones 
or anti-muscarinic agents) are available over the counter.
Despite the social health costs [8], it emerges that 
generally AR is underestimated, often poorly controlled 
and undertreated. Thus, a more detailed education for 
healthcare workers and patients would be needed and a 
better awareness of the disease should be disseminated. 
It is true that, so far, there are no predictive biomarkers 
to appropriately address the therapeutic approach, or to 
predict the response, for instance, to AIT [9]. Accord-
ing to these considerations, in the last decade greater 
attention has been devoted to a more comprehensive 
approach to AR [10], looking specifically to the sever-
ity of symptoms, exacerbations, impact on the quality of 
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life, course of disease, use of medications. The web-based 
instruments are a promising example of the possibility of 
day-by-day monitoring of patients [3].
Currently in real life the most feasible and practical 
instrument to evaluate the presence, severity and control 
of symptoms remains the Visual Analogue Scale (VAS), 
consisting in a single patient-reported outcome of the 
effect of the disease and of the treatment. Patients with a 
VAS > 5 are considered not controlled [11–13]. Accord-
ingly, most patients agreed that VAS evaluation could be 
considered a good instrument [14, 15].
Other instruments to assess the impact of AR are avail-
able, for example the CARAT (“Control of Allergic Rhi-
nitis and Asthma Test”) questionnaire evaluates in few 
questions the perceived control of AR and concomitant 
asthma, also assessing the overall use of pharmacother-
apy [16]. Other more detailed questionnaires are also 
available. It has been identified that the major reasons for 
an unsatisfactory control of rhinitis are incorrect diag-
nosis, intrinsic severity of the disease [17], incorrect use/
misuse of the intranasal treatment [11].
The aim of this study was to assess through the use of 
VAS and CARAT instruments the level of control of AR 
in patients (>  16  years) without previous asthma diag-
nosis referred to Allergy Centers. The possible causes of 
poor control were also further investigated.
Methods
This was a multi-center observational cross-sectional 
study involving patients with AR, referred for the first 
time to Allergy centers of Northern Italy (Turin, Verona, 
Parma, Brescia) between May and December 2015. Only 
patients with ascertained symptoms of AR in the previ-
ous month and without a previous asthma diagnosis were 
included. The level of control was assessed by the VAS 
(0 = troublesome symptoms, 10 = no symptoms) and the 
CARAT instrument [16]. CARAT is a tool created and 
validated to measure disease control of both allergic rhi-
nitis and asthma. It is a self-administered questionnaire 
that quantifies not only nasal, ocular, oropharyngeal, 
lower respiratory tract symptoms, sleep impairment, 
activities, psychosocial impediments, but also treatment 
and exacerbation. The more the patient is symptomatic 
and has a poor quality of life, the lower the CARAT score. 
In addition, the relevant demographic and clinical data 
(age, sex, duration of the disease, allergen sensitizations) 
were recorded for the analyses. The type of medications 
(e.g. antihistamines, nasal steroids, decongestants), their 
frequency of dosing and possible incremental use were 
assessed. The AR was better controlled when the VAS 
was lower and the CARAT scores were higher.
All statistical procedures were performed using the sta-
tistical package STATA version 14 for Windows  [STATA® 
(Stata Corp-LP-College Station-TX-USA)] [18]. All tests 
of significativity were carried out at a 0.05 level. For the 
analysis of symptom severity and symptomatic treatment 
changes, the ratings “present always, never, less than or 
more than 2/week” were used. Age was categorized in 
10-year intervals. The time of symptoms’ duration was 
classified as < 1, 1–4, 5–10, 11–20, > 20 years. All catego-
rized variables were used in the analysis as ordinal vari-
ables when appropriate. The relationship between VAS 
and symptoms score was measured by means of quantile 
(median) regression with VAS-score as dependent and 
Symptom-score as predictive variables [19–21].
Statistical methods were used to investigate which fac-
tors could influence the VAS score and the relationship 
between VAS score (dependent variables) and symptoms, 
medication use and life quality.
Ordinal logistic regression with VAS score as depend-
ent variable, measuring the increase in the log odds of 
being in a higher level of VAS-score for a class increase in 
each predictive variable (i.e., going from 0 to 4), given all 
the other variables in the model are held stable. The Par-
allel Regression Assumption was tested by Brant Test [20, 
21]. The same analysis was repeated by means of bino-
mial logistic regression categorizing VAS score as < 5 or 
≥ 5. The predicted marginal probabilities of VAS ≥ 5 (in 
% scale) were computed and reported by age strata. To 
assess the influence of category of drug used on the prob-
ability of VAS > 5 we performed logistic model analysis. 




Within the considered period, 250 patients (54% female, 
age between 16 and 80 years, 2% over 65 years) were stud-
ied (Table  1). Overall 45% of patients had symptoms of 
AR for less than 5 years, and 12% of the patients reported 
a persistence of symptoms greater than 20  years. Most 
patients reported no comorbidity associated with rhinitis 
and among patients with comorbid conditions 20.8% had 
nasal polyposis and 2.6% had an acetylsalicylic acid-exac-
erbated disease. 79% were polysensitized, mainly to grass 
(68.4%), house dust mites (38%) and cat dander (31.6%). 
In 52% of the cases the most frequently reported symp-
tom was nasal obstruction (daily or >  2/week). 29% of 
patients reported mild obstruction, whereas 18% had no 
obstruction during the previous 4 weeks. The second rel-
evant symptom was rhinorrhea, frequent in 50%, mild in 
33% and absent in 17%. Sneezing and itching were overall 
less frequent. According to the ARIA guidelines [1], 34% 
patients reported a relevant impact of AR on their daily 
activities. Nocturnal awakenings were reported by 52% of 
patients (Table 2). 
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Within the population, 71% of patients (178/250) were 
assuming symptomatic drugs, such as antihistamines 
(68% as regular treatment and 32% on demand), nasal 
steroids (75% regular and 25% on demand), nasal lavages 
(14% on demand). 59% of the subjects taking any therapy 
did not report an increase in drug consumption for more 
than 1 week/month.
Risk factors of severe disease
More importantly, 62% of the patients scored a VAS ≥ 5, 
suggesting a non-optimal control of the disease in the 
previous last 4 weeks. By the median regression, a nega-
tive weak correlation (Spearman’s rho = − 0.65 p < 0.01) 
was seen between VAS and symptom scores (Fig. 1). The 
ordinal logistic regression analysis showed that, control-
ling for other symptoms, the probability of an higher 
VAS-score level increases significantly with stuffy nose 
and sneezing symptoms (OR 2.06–CI 95% 1.57–2.71), 
quality of life compromised (OR 1.64 CI 95% 1.17–2.28) 
and night awakenings (OR 1.44 CI 95% 1.03–2.00) 
(Table 3). In those patients with uncontrolled AR, nasal 
obstruction resulted to be the most relevant symptom. 
The risk of uncontrolled disease is associated consid-
ering the probability of having VAS score > 5 (as lack of 
control of disease) the logistic regression analysis showed 
that itching and nocturnal awakenings have less influence 
on the control of AR (Table  4) than nasal obstruction 
and sneezing frequency. The frequency of nasal obstruc-
tion in linearly associated with VAS score > 5, (OR 1.78 
for each nasal obstruction frequency grade, CI 95% 
1.24–2.55) (Fig.  2). There was no significant association 
between control of the disease and demographic charac-
teristics (age, sex, comorbidities, duration of the disease). 
Treatment of rhinitis
In patients with uncontrolled disease (VAS > 5), oral anti-
histamines were the most used medications (p = 0.005), 
whereas nasal steroids (as suggested by ARIA guidelines) 
were less used (p = 0,604) and allergen immunotherapy 
was the least employed (p = 0.037) (Table 5). In patients 
who needed to increase therapy (23/178), the most used 
drugs were steroids, both topical and systemic, and the 
steroid/antihistamine topical combination.
Discussion and conclusions
It is well known that AR is considered as a “trivial” dis-
order in the general population. Nonetheless, it probably 
remains the most common immune-mediated disease, 
with prevalence continuously increasing, and being 
responsible for a not negligible economic burden in term 
of absenteism or presenteeism [22, 23]. It has recently 
become clear that, despite the easy diagnosis, AR remains 
often uncontrolled or inappropriately treated. This can 
Table 1 Demographic data of the population
Sex
 Male 115/250 (46%)
 Female 135/250 (54%)
Age range (years)
 10–20 45/250 (18%)
 20–45 143/250 (57%)
 45–65 57/250 (23%)
 > 65 5/250 (2%)
Onset of symptoms (years)
 1–5 113/250 (43%)
 5–10 37/250 (15%)
 10–20 70/250 (28%)
 > 20 30/250 (12%)
Allergen sensitization
 Monosensitized 52/250 (21%)
 Polysensitized 198/250 (79%)
Table 2 Symptoms frequency
Nasal obstruction
 Never 45/250 (18%)
 1–2/week 73/250 (29%)
 > 2/week 72/250 (29%)
 Always 59/250 (23%)
Rhinorrhea
 Never 42/250 (17%)
 1–2/week 82/250 (33%)
 > 2/week 74/250 (29%)
 Always 52/250 (21%)
Sneezing
 Never 34/250 (14%)
 1–2/week 94/250 (38%)
 > 2/week 66/250 (26%)
 Always 56/250 (22%)
Itching
 Never 61/250 (24%)
 1–2/week 89/250 (36%)
 > 2/week 65/250 (26%)
 Always 35/250 (14%)
Quality of life
 Never 77/250 (31%)
 1–2/week 85/250 (34%)
 > 2/week 70/250 (28%)
 Always 18/250 (7%)
Awakenings
 Never 119/250 (48%)
 1–2/week 68/250 (27%)
 >2/week 53/250 (21%)
 Always 10/250 (4%)
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have a reflection on the natural history of the disease, as 
AR is the most relevant risk factor for the future devel-
opment of allergic asthma [24–26]. In this multi-center 
cross-sectional study, conducted in Northern Italy, we 
aimed at evaluating the level of control of AR by means of 
a simple tool, the VAS, that can be easily filled by patients 
and reflects the presence of symptoms and their burden 
in the previous month. A VAS score  >  5 suggests a not 
satisfactory control of symptoms. This parameter was 
correlated with CARAT, single symptoms, and the con-
sumption of AR-related drugs. More than 60% of the 
patients analysed had an uncontrolled AR, providing 
evidence in line with the available literature data [4]. A 
European survey evidenced that a satisfactory control 
of AR symptoms can be achieved only in about 45% of 
the patients, independently of the drugs used [23]. It is 
also true that in our survey, including selected patients, 
only about one half was using multiple medications, and 
that only a minority was undergoing AIT. This survey 
confirmed that the VAS assessment is a reliable clini-
cal tool, as it well correlates with the structured CARAT 
questionnaire and with the relevant symptoms of AR. In 
our study, nasal obstruction, the quality of life and noc-
turnal awakenings significantly impacted on the VAS, but 
the best index of the failure to control was the presence 
of nasal obstruction. Even this observation conforms to 
what can be found in the literature, as nasal obstruction 
Fig. 1 Median regression of VAS score versus symptoms-score
Table 3 Risk of higher VAS-symptoms score by QoL 
and CARAT items score adjusted each-other and for age 
by means of ordinal logistic regression)
VAS-score Odds ratio 95% CI p value
Age (media 34 years old) 0.98 0.97 1.00 0.020
Nasal obstruction (204/250) 2.06 1.57 2.71 0.000
QoL (169/250) 1.64 1.17 2.28 0.004
Awakenings (131/250) 1.44 1.03 2.00 0.031
Itching (189/250) 1.20 0.91 1.58 0.191
Drug consumption (178/250) 1.22 0.80 1.86 0.349
Table 4 Risk of VAS > 5—uncontrolled disease—by level 
of CARAT item (categorical) controlling each-other
Result of logistic regression analysis using VS > 5 as dependent and CARAT Items 
as predictive variables
Odds ratio 95% Confidence interval p value
Nasal obstruction
 Never 2.04 0.74–5.60 0.168
 1–2/week 3.59 1.21–10.63 0.021
 > 2/week 6.76 1.87–24.50 0.004
 Linear trend 1.78 1.24–2.55 0.002
Sneezing
 Never 0.32 0.10–1.03 0.056
 1–2/week 1.34 0.37–4.88 0.655
 > 2/week 6.84 1.17–40.11 0.033
 Linear trend 1.99 1.27–3.13 0.003
Itching
 Never 3.43 1.30–9.05 0.013
 1–2/week 2.58 0.83–8.09 0.103
 > 2/week 3.21 0.60–17.22 0.173
 Linear trend 1.52 0.99–2.33 0.053
Awakenings
 Never 1.44 0.59–3.50 0.421
 1–2/week 3.63 1.09–12.03 0.035
 > 2/week 2.38 0.20–28.40 0.493
 Linear trend 1.67 1.04–2.69 0.034
Fig. 2 Probability of VAS score > 5 by nasal obstruction frequency, 
adjusted for other CARAT items by means of logistic regression 
analysis
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is the most difficult symptom to treat being it reported 
by most troublesome patients. This finding suggests to 
always evaluate this symptom as a predictive marker of 
poor control of the disease. We could not show any cor-
relation between the lack of AR control and asthma, since 
our patients were selected without asthma and in a cross-
sectional fashion [18, 19]. Finally, the most alarming fact 
that emerges is that the ARIA guidelines are still poorly 
followed. In fact, our AR patients, even if not controlled, 
mainly used antihistamines but not nasal steroids. Also, 
AIT is poorly used in our sample, although this obser-
vation could be biased by the fact that the most part of 
patients was at the first allergologic visit. Our series 
included patients who came after the evaluation of gen-
eral practitioners, post-Emergency Room or specialists 
(ENT, paediatricians, pulmonologists). This suggests that 
not only general practitioners, but also other medical 
categories ignore or do not follow the ARIA guidelines, 
which must therefore have a greater circulation in order 
to obtain a better control of allergic rhinitis.
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